Kanamycin

Amantadine is an oral antiviral agent with immunomodulatory effects that was used extensively against influenza and later investigated as a possible therapy for chronic hepatitis C. In the kidney-transplant setting, its significance lies less in therapeutic success than in the clarity of the distinction it exposes: improved liver-enzyme measurements did not translate into clearance of HCV or recovery of liver histology, while renal impairment and treatment-related anemia narrowed the practical scope of its use.

Nature and Proposed Role

Amantadine was considered because earlier studies in patients with chronic hepatitis C had reported improved aminotransferase levels, and because the drug was thought capable of potentiating the antiviral effect of interferon and ribavirin. That proposed role placed it within an older therapeutic landscape, before direct-acting antiviral drugs transformed treatment expectations. The rationale was therefore twofold: amantadine might exert an antiviral effect of its own, and its immunomodulatory properties might strengthen combination treatment.

The broader hepatitis C framework made the distinction between laboratory response and active infection especially important. Chronic infection was defined by the coexistence of anti-HCV antibodies and detectable HCV RNA, while evaluation also required attention to hepatic fibrosis and extrahepatic disease. Against that standard, a fall in aminotransferase activity could indicate biochemical improvement without demonstrating eradication of the virus.

Evidence in Kidney Transplant Recipients

Data in HCV-positive kidney-transplant recipients were limited. In an open pilot study, eight recipients with chronic active hepatitis and increased alanine aminotransferase levels received amantadine monotherapy at 200 mg per day for six months. The treatment produced a statistically significant decline in alanine aminotransferase activity, from 100 plus or minus 9 IU/l at baseline to 71 plus or minus 17 IU/l at month six. Aspartate aminotransferase also declined, but the change did not reach statistical significance.

The more decisive measures remained unchanged. HCV viremia did not fall significantly: the reported level was 5.87 plus or minus 0.37 log copies/ml at month six, compared with 5.71 plus or minus 0.5 log copies/ml at baseline. Liver histology likewise showed no significant change. Clinical and biological tolerance was described as very good, but the study concluded that amantadine monotherapy lacked efficacy in these recipients because it improved liver-enzyme levels without affecting either HCV viremia or liver histology.

Combination with Ribavirin

Amantadine was also tested in combination with ribavirin in a prospective randomized controlled study of HCV-positive kidney-transplant patients. The study assigned seven patients to ribavirin at 1,000 mg daily, eight to ribavirin at 1,000 mg daily plus amantadine at 200 mg daily, and twenty-six to a no-treatment control group; treatment continued for twelve months. No significant differences emerged among the groups in liver-enzyme levels, HCV viremia, liver histology, or renal parameters.

The trial was further constrained by tolerability. Antiviral treatment had to be limited because of anemia, leading to premature withdrawal in some patients and the use of recombinant erythropoietin in most of them. A creatinine-clearance rate above 50 ml/min was the strongest predictor of tolerability, linking the feasibility of treatment directly to residual renal function. The combination of amantadine and ribavirin was therefore not superior to ribavirin alone, although impaired renal function and consequent poor tolerance may have produced dropouts and subtherapeutic dosing that weakened the comparison.

Clinical Significance and Limitations

The evidence places amantadine among treatments that could improve surrogate biochemical markers without achieving the central objectives of hepatitis C therapy. In the kidney-transplant population, neither monotherapy nor combination with ribavirin demonstrated HCV-RNA clearance. This limitation was particularly consequential because other older options were also problematic: pegylated interferon alone produced very low sustained virologic response rates in immunocompromised recipients and could impair the renal allograft, chiefly by triggering acute rejection.

Amantadine’s apparent safety in the small monotherapy pilot did not resolve the larger therapeutic problem. In the randomized study, anemia restricted exposure, renal dysfunction reduced tolerability, and the resulting dose limitations may have obscured any modest pharmacologic effect. The available evidence therefore supports a narrow conclusion: amantadine could lower aminotransferase activity in some kidney-transplant recipients, but it did not provide convincing antiviral or histologic benefit and did not improve the outcome of ribavirin-based treatment.

Place in the Evolution of Hepatitis C Therapy

Amantadine belongs to a transitional phase in hepatitis C treatment, when clinicians were testing oral agents and combinations in an effort to improve on interferon-based therapy. That period eventually gave way to direct-acting antiviral drugs aimed at specific viral enzymes, including protease and polymerase inhibitors, whose development was driven by a more precise understanding of the viral cycle. In that context, amantadine’s record illustrates why biochemical response alone could no longer be treated as proof of therapeutic success.

Its importance is consequently historical and evaluative as much as pharmacological. The drug helped establish, through negative or incomplete results, that lower enzyme values were insufficient when HCV RNA remained detectable and liver histology unchanged. For HCV-positive kidney-transplant recipients—patients already exposed to immunosuppression, allograft dysfunction, anemia, and reduced renal clearance—the evidence did not justify treating amantadine as a reliable means of viral eradication.